These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 1964791)

  • 1. Advanced nonenzymatic tissue glycosylation: cell-mediated interactions implicated in the complications associated with diabetes and aging.
    Vlassara H
    Blood Purif; 1990; 8(4):223-32. PubMed ID: 1964791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage receptor-mediated processing and regulation of advanced glycosylation endproduct (AGE)-modified proteins: role in diabetes and aging.
    Vlassara H; Brownlee M; Cerami A
    Prog Clin Biol Res; 1989; 304():205-18. PubMed ID: 2550952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic diabetic complications and tissue glycosylation. Relevant concern for diabetes-prone black population.
    Vlassara H
    Diabetes Care; 1990 Nov; 13(11):1180-5. PubMed ID: 2261839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues.
    Vlassara H
    Diabetes; 1992 Oct; 41 Suppl 2():52-6. PubMed ID: 1326453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Macrophage/monocyte receptor for nonenzymatically glycosylated protein is upregulated by cachectin/tumor necrosis factor.
    Vlassara H; Moldawer L; Chan B
    J Clin Invest; 1989 Dec; 84(6):1813-20. PubMed ID: 2556447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Advanced glycation end products stimulate tumor necrosis factor-alpha and interleukin-1 beta secretion by peritoneal macrophages in patients on continuous ambulatory peritoneal dialysis.
    Rashid G; Korzets Z; Bernheim J
    Isr Med Assoc J; 2006 Jan; 8(1):36-9. PubMed ID: 16450750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Receptor-specific induction of insulin-like growth factor I in human monocytes by advanced glycosylation end product-modified proteins.
    Kirstein M; Aston C; Hintz R; Vlassara H
    J Clin Invest; 1992 Aug; 90(2):439-46. PubMed ID: 1322940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1.
    Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H
    J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling.
    Vlassara H; Brownlee M; Manogue KR; Dinarello CA; Pasagian A
    Science; 1988 Jun; 240(4858):1546-8. PubMed ID: 3259727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins.
    Yang Z; Makita Z; Horii Y; Brunelle S; Cerami A; Sehajpal P; Suthanthiran M; Vlassara H
    J Exp Med; 1991 Sep; 174(3):515-24. PubMed ID: 1651976
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Advanced glycosylation end products (AGE): new toxins?].
    Boulanger E; Dequiedt P; Wautier JL
    Nephrologie; 2002; 23(7):351-9. PubMed ID: 12500421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products.
    Schwenger V; Morath C; Salava A; Amann K; Seregin Y; Deppisch R; Ritz E; Bierhaus A; Nawroth PP; Zeier M
    J Am Soc Nephrol; 2006 Jan; 17(1):199-207. PubMed ID: 16319192
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Biochemical properties and clinical significance of protein glycation products].
    Staniszewska M; Gamian A
    Postepy Hig Med Dosw; 2003; 57(2):123-47. PubMed ID: 12866352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Protein glycation--clinical and chemical aspects].
    Szymańska U; Boratyński J
    Postepy Hig Med Dosw; 1999; 53(5):689-703. PubMed ID: 10645144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advanced nonenzymatic glycation endproducts (AGE): their relevance to aging and the pathogenesis of late diabetic complications.
    Sensi M; Pricci F; Andreani D; Di Mario U
    Diabetes Res; 1991 Jan; 16(1):1-9. PubMed ID: 1818791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Glycation and protein crosslinking in the diabetes and ageing pathogenesis].
    Cárdenas-León M; Díaz-Díaz E; Argüelles-Medina R; Sánchez-Canales P; Díaz-Sánchez V; Larrea F
    Rev Invest Clin; 2009; 61(6):505-20. PubMed ID: 20184132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of advanced glycation end-products on gene expression and synthesis of TNF-alpha and endothelial nitric oxide synthase by endothelial cells.
    Rashid G; Benchetrit S; Fishman D; Bernheim J
    Kidney Int; 2004 Sep; 66(3):1099-106. PubMed ID: 15327404
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advanced glycosylation end products: a new disease marker for diabetes and aging.
    Wu JT
    J Clin Lab Anal; 1993; 7(5):252-5. PubMed ID: 8410484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs.
    Thornalley PJ
    Cell Mol Biol (Noisy-le-grand); 1998 Nov; 44(7):1013-23. PubMed ID: 9846883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.
    Vlassara H; Bucala R; Striker L
    Lab Invest; 1994 Feb; 70(2):138-51. PubMed ID: 8139257
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.